Tags

Type your tag names separated by a space and hit enter

[Clinical management of rheumatic immune-related adverse events : Recognize and treat rheumatological side effects of checkpoint inhibition].
Z Rheumatol. 2020 Jul 01 [Online ahead of print]ZR

Abstract

Immune checkpoint inhibitors (ICPi) represent a major breakthrough in the treatment and prognosis of many cancers, particularly of malignant melanoma and non-small cell lung cancer; however, the high tumor response rates with ICPi are also frequently associated with autoimmune side effects, so-called immune-related adverse events (irAEs), which can involve virtually any organ system and mirror classical autoimmune diseases. Recent studies revealed that around 5-20% of patients treated with ICPi experience rheumatic irAEs covering the full spectrum of inflammatory rheumatic diseases. This article summarizes the state of the art of knowledge with respect to diagnostics and management of this newly recognized disease entity in rheumatology.

Authors+Show Affiliations

Sektion Rheumatologie, Innere Medizin V, Universitätsklinik Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland. karolina.benesova@med.uni-heidelberg.de.Sektion Rheumatologie, V. Medizinische Klinik, Universitätsklinik Mannheim, Mannheim, Deutschland. Sektion Rheumatologie und Klinische Immunologie, Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-Universität München, München, Deutschland.

Pub Type(s)

English Abstract
Journal Article

Language

ger

PubMed ID

32613268

Citation

Benesova, K, and J Leipe. "[Clinical Management of Rheumatic Immune-related Adverse Events : Recognize and Treat Rheumatological Side Effects of Checkpoint Inhibition]." Zeitschrift Fur Rheumatologie, 2020.
Benesova K, Leipe J. [Clinical management of rheumatic immune-related adverse events : Recognize and treat rheumatological side effects of checkpoint inhibition]. Z Rheumatol. 2020.
Benesova, K., & Leipe, J. (2020). [Clinical management of rheumatic immune-related adverse events : Recognize and treat rheumatological side effects of checkpoint inhibition]. Zeitschrift Fur Rheumatologie. https://doi.org/10.1007/s00393-020-00825-z
Benesova K, Leipe J. [Clinical Management of Rheumatic Immune-related Adverse Events : Recognize and Treat Rheumatological Side Effects of Checkpoint Inhibition]. Z Rheumatol. 2020 Jul 1; PubMed PMID: 32613268.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Clinical management of rheumatic immune-related adverse events : Recognize and treat rheumatological side effects of checkpoint inhibition]. AU - Benesova,K, AU - Leipe,J, Y1 - 2020/07/01/ PY - 2020/7/3/entrez KW - Autoimmune diseases KW - Autoimmune side effects KW - Immune checkpoint inhibitors KW - Immunotherapy side effects KW - Malignancy JF - Zeitschrift fur Rheumatologie JO - Z Rheumatol N2 - Immune checkpoint inhibitors (ICPi) represent a major breakthrough in the treatment and prognosis of many cancers, particularly of malignant melanoma and non-small cell lung cancer; however, the high tumor response rates with ICPi are also frequently associated with autoimmune side effects, so-called immune-related adverse events (irAEs), which can involve virtually any organ system and mirror classical autoimmune diseases. Recent studies revealed that around 5-20% of patients treated with ICPi experience rheumatic irAEs covering the full spectrum of inflammatory rheumatic diseases. This article summarizes the state of the art of knowledge with respect to diagnostics and management of this newly recognized disease entity in rheumatology. SN - 1435-1250 UR - https://www.unboundmedicine.com/medline/citation/32613268/[Clinical_management_of_rheumatic_immune-related_adverse_events_:_Recognize_and_treat_rheumatological_side_effects_of_checkpoint_inhibition] L2 - https://dx.doi.org/10.1007/s00393-020-00825-z DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.